Gotham Asset Management LLC Acquires 5,099 Shares of Natera, Inc. $NTRA

Key Points

• Gotham Asset Management LLC increased its stake in Natera, Inc. by 4.7%, owning approximately 0.08% of the company, valued at $16.2 million.
• Several institutional investors, including Vanguard Group and Price T Rowe Associates, also boosted their positions in Natera during the first quarter, indicating strong institutional confidence in the stock.
• Natera reported a revenue of $546.6 million for the last quarter, significantly outperforming analyst estimates and marking a 32.2% year-over-year increase.

Gotham Asset Management LLC boosted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 4.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,603 shares of the medical research company's stock after purchasing an additional 5,099 shares during the quarter. Gotham Asset Management LLC owned about 0.08% of Natera worth $16,206,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of NTRA. Vanguard Group Inc. raised its position in shares of Natera by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock valued at $1,752,611,000 after buying an additional 77,357 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after acquiring an additional 660,538 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Natera by 13.7% in the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after acquiring an additional 245,719 shares during the last quarter. Finally, Maverick Capital Ltd. lifted its holdings in shares of Natera by 19.7% in the 1st quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company's stock valued at $231,173,000 after acquiring an additional 268,715 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Price Performance

NTRA stock traded up $8.98 during mid-day trading on Tuesday, reaching $176.37. The company had a trading volume of 1,296,953 shares, compared to its average volume of 1,478,578. The company has a market capitalization of $24.21 billion, a PE ratio of -92.34 and a beta of 1.68. The firm has a 50 day moving average of $154.63 and a 200 day moving average of $153.87. Natera, Inc. has a 12 month low of $114.62 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insiders Place Their Bets

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director owned 8,118 shares in the company, valued at $1,358,628.48. This represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,423 shares of company stock worth $8,459,656. 5.63% of the stock is owned by company insiders.

Analysts Set New Price Targets

NTRA has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 price target on shares of Natera in a report on Sunday, August 10th. Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target for the company in a report on Monday, July 28th. Finally, Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.